Anson Funds Management LP Buys Shares of 1,462,112 TransCode Therapeutics Inc. $RNAZ

Anson Funds Management LP bought a new position in shares of TransCode Therapeutics Inc. (NASDAQ:RNAZ) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,462,112 shares of the company’s stock, valued at approximately $724,000. Anson Funds Management LP owned about 1.76% of TransCode Therapeutics at the end of the most recent quarter.

Separately, Warberg Asset Management LLC acquired a new stake in TransCode Therapeutics during the 1st quarter valued at $25,000.

TransCode Therapeutics Stock Performance

RNAZ stock opened at $10.70 on Thursday. TransCode Therapeutics Inc. has a 52-week low of $6.15 and a 52-week high of $739.20. The stock’s fifty day simple moving average is $10.31 and its 200-day simple moving average is $15.75.

TransCode Therapeutics (NASDAQ:RNAZ) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($4.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.68) by $3.74. Equities research analysts predict that TransCode Therapeutics Inc. will post -4.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded TransCode Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 30th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $280.00.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.